TROMLIEVA 50 mg contains Eltrombopag Olamine, an oral thrombopoietin (TPO) receptor agonist. It increases platelet production by stimulating the c-Mpl receptor on megakaryocyte progenitor cells in the bone marrow, thereby raising platelet counts.

Eltrombopag is indicated for:

1. Chronic Immune (Idiopathic) Thrombocytopenia (ITP)
     – In patients not responding adequately to corticosteroids, IVIG, or splenectomy

2. Severe Aplastic Anemia
     – Refractory cases or in combination with immunosuppressive therapy

3. Thrombocytopenia in Chronic Hepatitis C
    – To enable initiation and maintenance of interferon-based therapy (where applicable)

Common side effects:

•   Headache

•   Nausea, diarrhea

•   Fatigue

•   Elevated liver enzymes

Serious side effects:

•   Hepatotoxicity

•   Thromboembolic events

•   Cataract formation (long-term use)

•   Bone marrow reticulin fibrosis (rare)

Regular monitoring of platelet count and liver function tests is mandatory.

Dose is individualized according to indication and platelet response.

Typical dosing:

•   50 mg once daily (standard starting dose for many adult patients)

•   Dose adjustments made in steps of 25 mg based on platelet counts

•   Maximum dose usually 75 mg/day

50 mg strength is commonly used as a maintenance or escalation dose.


NOTE: This medicine should be taken only under a doctor’s supervision.